CureVac N.V.
CVAC
$5.44
-$0.05-0.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 786.89% | 896.67% | 626.78% | 81.95% | 22.11% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 786.89% | 896.67% | 626.78% | 81.95% | 22.11% |
| Cost of Revenue | -53.01% | -9.07% | 13.47% | 25.81% | 0.49% |
| Gross Profit | 685.85% | 789.22% | 308.90% | -1.82% | 11.34% |
| SG&A Expenses | -22.61% | -22.28% | -10.07% | -14.34% | -10.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 37.00% | -42.34% | 53.58% | 65.34% | 62.60% |
| Total Operating Expenses | -13.96% | 0.67% | 18.70% | 22.13% | 20.42% |
| Operating Income | 184.38% | 180.50% | 84.48% | -13.25% | -20.07% |
| Income Before Tax | 177.35% | 173.63% | 80.23% | 5.04% | 2.36% |
| Income Tax Expenses | 3,191.59% | 14,448.48% | 23,969.41% | 16,013.10% | 3,452.69% |
| Earnings from Continuing Operations | 166.71% | 162.53% | 74.92% | 4.30% | 2.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 166.71% | 162.53% | 74.92% | 4.30% | 2.04% |
| EBIT | 184.38% | 180.50% | 84.48% | -13.25% | -20.07% |
| EBITDA | 195.97% | 192.86% | 89.86% | -15.27% | -25.97% |
| EPS Basic | 166.66% | 161.58% | 76.77% | 13.74% | 15.05% |
| Normalized Basic EPS | 193.88% | 217.61% | 85.85% | -32.07% | -31.51% |
| EPS Diluted | 166.30% | 161.22% | 76.55% | 13.74% | 15.04% |
| Normalized Diluted EPS | 193.88% | 217.61% | 85.85% | -32.07% | -31.51% |
| Average Basic Shares Outstanding | 0.21% | 1.59% | 5.39% | 9.71% | 14.82% |
| Average Diluted Shares Outstanding | 0.21% | 1.59% | 5.39% | 9.71% | 14.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |